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Received May 29, 2013; accepted August 8, 2013AbstractBackground: Previous studies have reported that the attainment of goals for low-density lipoprotein cholesterol (LDL-C) are globally subop-
timal, but contemporary data are scarce. The CEntralized Pan-Asian survey on tHE Under-treatment of hypercholeSterolemia (CEPHEUS-PA) is
the largest evaluation of pharmacological treatment for hypercholesterolemia in Asia. The study reported here analyzed the Taiwan cohort in
CEPHEUS-PA to identify the determinants of successful treatment.
Methods: The patients eligible for this study were adults (18 years old) with hypercholesterolemia and with at least two coronary heart disease
(CHD) risk factors who had been receiving lipid-lowering drugs for at least 3 months before enrollment, without adjustment for at least 6 weeks
before enrollment. Demographic and clinical information and lipid concentrations were recorded. Cardiovascular risk levels and LDL-C targets
were determined using the updated Adult Treatment Panel III.
Results: In this group of 999 Taiwanese patients, 50%, 25%, and 24% had LDL-C goals set at <70 mg/dL, <100 mg/dL, and <130 mg/dL,
respectively. The overall attainment rate was 50%, with the lowest rate in patients set at the most stringent target (22%), followed by those whose
therapeutic goals were <100 mg/dL (69%) and <130 mg/dL (87%). The success of LDL-C control was lower in patients with multiple risk
factors other than CHD or its equivalents than in those without these multiple risk factors (37% vs. 53%, p < 0.001), and lower in patients with
metabolic syndrome than in those without (43% vs. 66%, p < 0.001). Baseline LDL-C and cardiovascular risk were inversely associated with
goal attainment, whereas treatment with statins was directly associated with the achievement of LDL-C goals. Patients with diabetes (odds ratio
0.49, 95% confidence interval 0.29e0.84, p ¼ 0.010) and with metabolic syndrome (odds ratio 0.15, 95% confidence interval 0.05e0.40,
p < 0.001) were less likely to be treated with statins.
Conclusion: This study showed that there is a discrepancy between the updated Adult Treatment Panel III recommendations for LDL-C control
and the control attained by this group of Taiwanese patients. In particular, treatment with statins was largely underused in patients with diabetes
and in those with metabolic syndrome. These findings highlight the need for more intensive treatment in high-risk patients and those with
multiple risk factors, particularly patients with metabolic syndrome.
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The growing burden of cardiovascular disease (CVD), as
shown by the increasing prevalence of coronary heart disease
(CHD) and stroke, is a significant global health issue.1
Treatment targeting low-density lipoprotein cholesterol
(LDL-C) has successfully reduced atherosclerosis and car-
diovascular complications.2,3 The greater decrease in LDL-C
achieved by the use of lipid-lowering drugs reflects propor-
tionally on the reduction in cardiovascular events, irrespective
of the risk levels of patients.4,5 The update of the Adult
Treatment Panel III6 (ATP III) of the National Cholesterol
Education Program recommends more rigorous LDL-C con-
trol, particularly for those patients at the highest risk with the
most stringent goal for LDL-C of <70 mg/dL.
Despite the increasing awareness of the need for the man-
agement of CHD, more than half of high-risk patients do not
attain the lipid levels recommended by the published guide-
lines.7e9 In Europe, the Centralized Pan-European Survey on
the Under-treatment of Hypercholesterolaemia indicated that
only 55% of patients receiving treatment attained the LDL-C
targets set by the 2003 European guidelines.10 The Lipid
Treatment Assessment Project 2 (L-TAP 2) study showed the
proportions of patients attaining the LDL-C goals recom-
mended by the ATP III, the 2003 European, or the Canadian
guidelines ranged from 47% to 84% across countries, whereas
only 30% of patients at very high risk attained optional LDL-C
levels of <70 mg/dL.11 In spite of the growing availability of
more effective lipid-lowering drugs, the failure of treatment
commonly involves multiple factors.12,13 The rate of cardio-
vascular events was higher in patients not attaining the rec-
ommended LDL-C targets.14e16Table 1
Cholesterol goals and cut-off points for drug treatment across different risk catego
ATP III update
LDL-C goal (mg/dL) C
tr
CHD or CHD risk equivalentsa <100 (optional <70)e 
2þ risk factorsb, 10-year risk >20% <100 
2þ risk factorsb, 10-year risk 10e20% <130 (optional: <100) 
2þ risk factorsb, 10-year risk <10% <130 
0e1 risk factorb <160 
ATP III ¼ Adult Treatment Panel III; CHD ¼ coronary heart disease; LDL-C ¼ low
cholesterol; TLC ¼ therapeutic lifestyle change.
a Abdominal aortic aneurysm, >50% carotid stenosis without previous stroke, a
bursement policy; brain hemorrhage is included in the NHI reimbursement policy.
b Risk factors in the NHI reimbursement policy do not include low levels of hig
c Reference from J Am Coll Cardiol 2004;44:720e32.
d Mandatory down-titration of lipid-lowering drugs once patients reach their the
e Patients categorized as very high risk with the presence of established cardiovasc
factors; multiple risk factors of the metabolic syndrome; and patients with acute c
f A drug to lower LDL-C is indicated simultaneously with TLC.
g A drug to lower LDL-C is indicated after TLC failure.It is of paramount importance to understand the de-
terminants of successful LDL-C control with regards to the
prevention of CVD. In Asia, the control rates of hypercho-
lesterolemia largely vary between countries and registries.17,18
However, differences at the country level have not been
analyzed in detail, and prognostic predictors have seldom been
explored. This study, as part of the CEntralized Pan-Asian
survey on tHE Under-treatment of hypercholeSterolemia
(CEPHEUS-PA), investigated the major determinants for
LDL-C goal attainment in Taiwan.
2. Methods2.1. Study designThe CEPHEUS-PA study (ClinicalTrials.gov Identifier
NCT00687492) was a prospective, cross-sectional survey of
patients with hypercholesterolemia receiving pharmacological
treatment. The study included patients from 405 sites across
eight Asian countries; the Taiwan section of this study was
conducted in eight hospitals in 2008.18 The protocol was
approved by the local institutional review board of each hos-
pital. Written informed consent was obtained from each
participant before they were enrolled into the study.2.2. PatientsEligible patients were adults (18 years) who had at least
two CHD risk factors defined by the ATP III update 2004 and
who had been treated with lipid-lowering drugs for at least 3
months, without adjustment for at least 6 weeks before
enrollment.ries in the ATP III update 2004 and Taiwan NHI reimbursement policy.
2004c Taiwan NHI reimbursement policyd

























-density lipoprotein cholesterol; NHI ¼ National Health Insurance; TC ¼ total
nd asymptomatic peripheral artery disease are not included in the NHI reim-
h-density lipoprotein cholesterol.
rapeutic goal.
ular disease plus: multiple major risk factors; severe and poorly controlled risk
oronary syndrome.
Table 2
Baseline characteristics in participants for full dataset analysis (n ¼ 999).
Variables Value
Age (y), mean  SD 65  11
Women, n 380
BMI (kg/m2), mean  SD 26  4
Waist circumference (cm), mean  SD 92  10
Hypertension, n 898
Smoking, n 241
Family history of premature CHD, n 283
HDL-C <40 mg/dL, n 304
Diabetes, n 488
Multiple risk factors with 10-year risk for CHD >20%, n 196
Metabolic syndrome, n 690
CHD, n 435
Carotid artery disease, n 103
Peripheral artery disease, n 10






Non-statin treatment, n 63
Duration of treatment (y), mean  SD 4  4
Last lipid values before lipid-lowering treatment started (mg/dL), mean  SDa
Total cholesterol 230  46
LDL-C 147  39
63K.-F. Wang et al. / Journal of the Chinese Medical Association 77 (2014) 61e67After patient consent had been obtained, data were
collected on patient demographics, cardiovascular risk factors,
history of CVD, the last available lipid concentrations before
enrollment, and current lipid-lowering treatment and in-
dications. The cardiovascular risk and the therapeutic LDL-C
goal of each patient were stratified according to the recom-
mendation of the ATP III update 2004.6,19 Blood was sampled
for lipid measurements after overnight fasting and was
analyzed at the local laboratory of the individual hospitals.
The objective of this analysis was to determine the pro-
portion of patients treated with lipid-lowering drugs who were
attaining the LDL-C goals set by the ATP III update 2004. The
major determinants for successful control were also
investigated.
Since 1995, Taiwan has instituted the National Health In-
surance (NHI), a single-payer compulsory healthcare program
that offers comprehensive medical coverage for more than
99% of the population. The reimbursement policy, which has
to provide a balance between the control of health spending
and the adoption of high-price treatments, has had an influence
on the prescription of drugs, particularly statins.20 Table 1
presents the differences between the recommendations of the
ATP III update 2004 and those of the Taiwan NHI reim-
bursement policy.HDL-C 45  12




Current lipid values (mg/dL), mean  SD
Total cholesterol 168  39
LDL-C 93  31
HDL-C 47  13
Triglyceride 152  90
BMI ¼ body mass index; CHD ¼ coronary heart disease; HDL-C ¼ high-
density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol.
a Per protocol analysis.Descriptive statistics included frequency distributions,
means and standard deviations. Potential factors that may
affect LDL-C goal attainment were investigated first in the
univariate analysis by logistic model analysis. The estimated
odds ratio (OR) and 95% confidence interval (CI) were
calculated. Factors with p < 0.1 in the univariate model were
further evaluated in the multivariate approach by the gener-
alized linear mixed model using the NLMIXED procedure of
the Statistics Analysis System statistical software (Cary, North
Carolina, United States). The NLMIXED procedure fits a
specified nonlinear mixed model by maximizing the approxi-
mation to the likelihood integrated over the random effects.
The variables included in the model were chosen based on the
p values of their effects in the model. Akaike’s Information
Criteria, F values and the number of nonmissing values were
also referred to in addition to p values in the model selection.
Variables were chosen and added to the model in the forward
selection mode to finalize the analysis. A value of p < 0.05
was considered statistically significant.
3. Results
From April 2008 to December 2008, 1072 participants were
enrolled, of which 999 qualified for the full data set analysis.3.1. Demographic profilesTable 2 gives the baseline demographics and characteristics
of the patients. With respect to CHD risk, hypertension and
diabetes were the most common risk factors; 20% of patientshad multiple risk factors with a 10-year risk >20%, and 69%
had metabolic syndrome (MetS). The most common CVD
(44%) was CHD, followed by carotid artery disease.
After stratification by cardiovascular risk and the updated
ATP III recommendations, 25% and 50% of the patients were
classified into high- and very high risk categories with targeted
LDL-C levels of <100 mg/dL and <70 mg/dL, respectively.
The duration of treatment with lipid-lowering drugs was 4  4
years and 66% of their use was indicated for secondary pre-
vention. The most common regimens included rosuvastatin
(39%) and atorvastatin (30%). Some statin users (36%)
received higher therapeutic doses (atorvastatin 20 mg, pra-
vastatin 40 mg, rosuvastatin 10 mg, and simvastatin
20 mg).
Based on the last-known lipid profiles available before
treatment began (baseline lipid levels), the concentrations of
total cholesterol, LDL-C, high-density lipoprotein cholesterol
(HDL-C) and triglyceride were 230  46 mg/dL (n ¼ 826),
147  39 mg/dL (n ¼ 583), 45  12 mg/dL (n ¼ 634), and
64 K.-F. Wang et al. / Journal of the Chinese Medical Association 77 (2014) 61e67220  229 mg/dL (n ¼ 826), respectively. The lipid concen-
trations measured in the survey were 168  39 mg/dL for total
cholesterol, 93  31 mg/dL for LDL-C, 47  13 mg/dL for
HDL-C and 152  90 mg/dL for triglyceride.3.2. LDL-C goal attainment and determinantsOverall, 50% of patients achieved the therapeutic LDL-C
targets set by the ATP III update 2004. Fig. 1 shows goal
attainment rates in the subgroups stratified by cardiovascular
risk and indications. Comorbid metabolic conditions and high
CHD risk predisposed to unfavorable LDL-C control rates
(53% vs. 46%, p ¼ 0.021 for patients without diabetes vs.
those with diabetes; 66% vs. 43%, p < 0.001 for patients
without MetS vs. those with MetS; 53% vs. 37%, p < 0.001
for patients with CHD risk 20% vs. patients with CHD risk
>20%). Goal attainment was inadequate in patients in the
higher risk categories (87% in the low/moderate risk patients,
69% in high-risk patients, 22% in very high risk patients,
p < 0.001). For therapeutic indications, patients treated for
primary prevention had a significantly greater proportion of
control success (58%), followed by those treated for familial
hypercholesterolemia (46%) and those treated for secondary
prevention (46%); in particular, only 39% of patients with
CHD attained their goals for LDL-C. In addition, treatment
with statins was associated with a higher rate of goal attain-
ment than treatment with nonstatins (51% vs. 32%,
p ¼ 0.004).
Table 3 presents the univariate predictors for LDL-C goal
attainment. Male sex, abdominal obesity, established risk
factors, CHD, and longer treatment times correlated with less
likelihood of achieving targeted LDL-C. Higher LDL-C tar-
gets, lower baseline total cholesterol and higher HDL-C were
positively related to goal attainment. Patients treated for sec-
ondary prevention had a significantly smaller probability of
attaining their goals than patients treated for primary preven-
tion. Moreover, patients treated with nonstatins were less
likely to attain their goals (OR 0.45, 95% CI 0.26e0.78,
p ¼ 0.004). In the multivariate model, higher LDL-C targets,Fig. 1. Percentage of patients treated for various cardiovascular risks and indication
coronary heart disease >20%. FH ¼ familial hypercholesterolemia; MetS ¼ metatreatment with statins, and lower baseline LDL-C were major
determinants for goal attainment.3.3. Determinants for treatment with statinsTreatment with statins was the major determinant for LDL-
C control and nearly 94% of the patients had been prescribed
statins. Table 3 shows the results of the univariate analysis for
allocation to treatment with statins. Patients with advanced
age, a family history of premature CHD, established CHD,
higher baseline LDL-C and HDL-C, and indication for sec-
ondary prevention were more likely to receive statins. In
contrast, a higher body mass index, the presence of diabetes
and the presence of MetS were associated with a lower like-
lihood of treatment with statins.
Fig. 2 shows the use of statins in subgroups stratified by
metabolic conditions and the components of MetS. Among the
components of MetS, impaired fasting glucose (OR 0.21, 95%
CI 0.10e0.47, p < 0.001), low HDL-C (OR 0.54, 95% CI
0.32e0.90, p ¼ 0.019) and increased triglyceride (OR 0.11,
95% CI 0.05e0.25, p < 0.001) were significantly associated
with a lower probability of treatment with statins, whereas
patients with abdominal obesity (OR 0.54, 95% CI 0.28e1.03,
p ¼ 0.062) had a trend towards a lower likelihood of treatment
with statins. In the multivariate model, increased triglyceride,
established CHD and baseline LDL-C were major de-
terminants for treatment with statins.4. Discussion
Our analysis showed that half of the patients indicated for
lipid-lowering drugs did not attain the recommended LDL-C
targets, with higher rates of nonattainment in the populations
at higher risk. This unsatisfactory result was directly related to
LDL-C concentrations before treatment as well as the drugs
selected for treatment. It was also found that statins were
underused in patients with metabolic conditions such as dia-
betes and MetS.s attaining their goals for low-density lipoprotein cholesterol. *10-year risk for
bolic syndrome.
Table 3
Univariate predictors for LDL-C goal attainment and allocation of treatment with statins.
LDL-C goal attainment Allocation to treatment with statins
OR (95% CI) p OR (95% CI) p
Age (y) 1.01 (0.99e1.02) 0.359 1.07 (1.04e1.10) <0.001
Women 1.42 (1.10e1.84) 0.007 1.16 (0.68e1.98) 0.584
BMI (kg/m2) 0.98 (0.94e1.01) 0.133 0.94 (0.88e1.00) 0.044
Waist circumference (cm) 0.97 (0.96e0.98) <0.001 0.98 (0.95e1.00) 0.075
Hypertension 0.63 (0.41e0.95) 0.029 1.14 (0.50e2.57) 0.757
Smoking 0.58 (0.43e0.78) <0.001 0.93 (0.52e1.68) 0.814
Family history of premature CHD 1.26 (0.95e1.66) 0.103 2.17 (1.09e4.33) 0.028
HDL-C <40 mg/dL 0.63 (0.48e0.83) <0.001 0.71 (0.42e1.20) 0.196
Diabetes 0.75 (0.58e0.96) 0.021 0.49 (0.29e0.84) 0.010
Multiple risk factors with 10-year risk for CHD >20% 0.54 (0.39e0.74) <0.001 0.94 (0.50e1.76) 0.837
Metabolic syndrome 0.39 (0.29e0.51) <0.001 0.15 (0.05e0.40) <0.001
CHD 0.48 (0.37e0.62) <0.001 5.77 (2.72e12.25) <0.001
Carotid artery disease 0.88 (0.58e1.32) 0.536 1.36 (0.53e3.46) 0.525
LDL-C target (mg/dL)
70 Reference <0.001 Reference 0.106
100 8.01 (5.70e11.27) 1.10 (0.56e2.15)
130 24.18 (15.68e37.30) 0.58 (0.32e1.03)
Duration of treatment (y) 1.00 (1.00e1.00) 0.560 0.99 (0.92e1.07) 0.840
Last lipid values before lipid-lowering therapya (mg/dL)
Total cholesterol 1.00 (0.99e1.00) 0.048 1.01 (1.00e1.01) 0.074
LDL-C 1.00 (0.99e1.00) 0.073 1.04 (1.03e1.05) <0.001
HDL-C 1.02 (1.01e1.03) 0.007 1.09 (1.04e1.13) <0.001
Treatment indication
Primary prevention Reference 0.002 Reference <0.001
Secondary prevention 0.60 (0.46e0.80) 3.04 (1.80e5.15)
Familial hypercholesterolemia 0.61 (0.31e1.19) 2.43 (0.56e10.53)
Type of treatment
Statins Reference 0.004 NA NA
Nonstatins 0.45 (0.26e0.78) NA
BMI ¼ body mass index; CHD ¼ coronary heart disease; CI ¼ confidence interval; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density li-
poprotein cholesterol; NA ¼ not applicable; OR ¼ odds ratio.
a Per protocol analysis.
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terolemia has been consistently reported throughout the last
century.16,21 As landmark studies indicated the advantages of
more aggressive lipid-lowering drugs, LDL-C targets stratified
by CHD risk were further lowered for patients at very high
risk.6,22 LDL-C goal attainment rates have been encouraging,
but are still suboptimal.10,11 The overall LDL-C control in
Asia has been reported across studies as inadequate compared
with the results presented in Western countries.17,18 TaiwanFig. 2. Allocation of patients with various levels of metabolic abnormalities to treatm
>80 cm for women; high blood pressure, 130/85 mmHg; impaired fasting gluc
<50 mg/dL in women; elevated triglyceride, triglyceride 150 mg/dL. HDL-C ¼and Korea were both included in recent surveys involving
Asian countries. The general LDL-C control rates were 66% in
Taiwan and 84% in Korea in the L-TAP 2 study, 24% and
42%, respectively, in the Return on Expenditure Achieved for
Lipid Therapy in Asia (REALITY-Asia) study, and 50% and
51%, respectively, in CEPHEUS-PA. The discrepancies across
registries were related mainly to differences in study pop-
ulations and designs. It is noteworthy that the majority of
patients enrolled in CEPHEUS-PA were at very highent with statins . Abdominal obesity, waist circumference >90 cm for men or
ose, fasting glucose 100 mg/dL; low HDL-C, HDL-C <40 mg/dL in men or
high-density lipoprotein cholesterol; MetS ¼ metabolic syndrome.
66 K.-F. Wang et al. / Journal of the Chinese Medical Association 77 (2014) 61e67cardiovascular risk and the therapeutic LDL-C target set by the
most stringent guideline was <70 mg/dL. By using the more
updated recommendation for patients at very high risk in the
L-TAP 2 study, the success rate was reduced to 30%, in
contrast with 73% based on the LDL-C goal set at <100 mg/
dL. However, it still represents a substantial improvement
since both the L-TAP 2 study and the REALITY-Asia study
were conducted in 2006.
There was agreement in these studies that the goal attain-
ment rate was higher in patients with relatively lower CHD
risk. It was further found that LDL-C targets were achieved in
only 46% of patients indicated for secondary prevention,
which was similar to data reported in other Asian coun-
tries.15,23 In both the L-TAP 2 and the REALITY-Asia studies,
LDL-C control was comparably insufficient in the higher risk
groups with the LDL-C target of <100 mg/dL set by the ATP
III. In our study, the LDL-C goal attainment rate of 43% in
patients with MetS was far from satisfactory. This is partially
attributed to the fact that MetS, with low HDL-C as one of its
components, is not included in the risk assessment for
atherosclerosis management and LDL-C targets in the Taiwan
NHI reimbursement policy.
The nonattainment of LDL-C goals was directly related to
the cardiovascular risk of patients, which also determined the
therapeutic target of the given patient. Other major de-
terminants included treatment with statins and LDL-C levels
before treatment with lipid-lowering drugs.
In our analysis, the presence of CHD and its risk and the
indication for secondary prevention increased the probability of
treatment with statins. However, those concomitant conditions
were negative predictors of LDL-C goal attainment. This could
be in part explained by the lower equipotency doses used in
clinical practice.24,25 A similar result was observed in the
REALITY-Asia study, in which <10% of the participants
received higher potency treatment.17 Moreover, our study
further suggested that an increase in treatment duration was
inversely related to LDL-C goal attainment (OR 0.94 per year,
95% CI 0.91e0.98, p ¼ 0.002). This finding also echoed the
results of a previous study showing that most of the patients at
the therapeutic targets achieved their LDL-C goals within the
first 3 months of treatment.17 In addition, the NHI reimburse-
ment policy mandates the reduction of lipid-lowering drugs
once therapeutic goals are achieved. The down-titration of
treatment may contribute to this “reverse epidemiology” phe-
nomenon with regard to lipid-lowering drugs. As longer treat-
ment did not necessarily translate into goal attainment, more
effective treatment and a follow-up strategy are required.
As MetS is not recognized in the risk evaluation in the NHI
reimbursement policy, decreased HDL-C and increased tri-
glyceride as components of MetS were attributable to a lower
likelihood of treatment with statins, which are more effica-
cious in the reduction of LDL-C. The treatment bias also led to
a lower LDL-C goal attainment rate in patients with MetS.
Patients with diabetes were also less likely to receive statins in
our analysis. This underuse of statin treatment in such sub-
groups of patients at high- or even very high risk is common in
other diseases and societies.26e29Finally, the concerns about the long-term safety of treatment
with statins might lead to under-prescription or noncompliance,
which compromises the favorable riskebenefit profiles of sta-
tins.30,31 Recent analyses have provided reassurance that the
benefits of lowering LDL-C using statins outweigh the risk of
incident diabetes, particularly in the population at highest risk
of CHD.32,33 The acknowledgement of the gaps between
guideline recommendations and clinical practice and the need
for more intensive treatment in patients with hypercholester-
olemia are important steps in delivering the comprehensive
management of CVD.
There are several limitations to this study that need to be
addressed. Firstly, the CEPHEUS-PA was cross-sectional and
observational in nature. The implications of under-treatment
with regard to long-term outcomes cannot be extrapolated.
Secondly, baseline lipid concentrations were not available
from medical records for every patient. Finally, this part of the
analysis focused on Taiwanese patients, who may not be
representative of a larger population receiving lipid-lowering
drugs.
In conclusion, the overall management of patients with
hypercholesterolemia is unsatisfactory and there is a need for
the better utilization of more effective treatment, particularly
in higher risk populations. Our findings emphasize the urgent
need to address the high number of patients who do not attain
their LDL-C goals, as this would narrow the gaps currently
seen between the benefits demonstrated in clinical trials and
those seen in real-world practice. Finally, the focus in sec-
ondary prevention for CHD should center not only on treating
hypercholesterolemia per se, but also on treating patients with
the aim of attaining the recommended targets referenced by
the practice guidelines to maximize the benefits to patients.
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